How have TTNP shares performed in 2023?

Titan Pharmaceuticals' stock was trading at $0.7831 at the beginning of 2023. Since then, TTNP stock has decreased by 55.3% and is now trading at $0.35. View the best growth stocks for 2023 here .

When is Titan Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024. View our TTNP earnings forecast .

How were Titan Pharmaceuticals' earnings last quarter?

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) posted its quarterly earnings results on Tuesday, March, 30th. The specialty pharmaceutical company reported ($0.86) EPS for the quarter, topping the consensus estimate of ($1.33) by $0.47. Titan Pharmaceuticals had a negative net margin of 2,021.31% and a negative trailing twelve-month return on equity of 302.61%.

When did Titan Pharmaceuticals' stock split?

Titan Pharmaceuticals shares reverse split on Tuesday, December 1st 2020. The 1-30 reverse split was announced on Monday, November 30th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, November 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Titan Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Titan Pharmaceuticals investors own include Bionano Genomics (BNGO) , Gran Tierra Energy (GTE) , Matinas BioPharma (MTNB) , Organigram (OGI) , Zosano Pharma (ZSAN) , Novan (NOVN) , ADMA Biologics (ADMA) , Aeterna Zentaris (AEZS) , CNBX Pharmaceuticals (CNBX) and Pennsylvania Real Estate Investment Trust (PEI) .

Who are Titan Pharmaceuticals' major shareholders?

Titan Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends .

How do I buy shares of Titan Pharmaceuticals?

Shares of TTNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Titan Pharmaceuticals Stock Price, News & Analysis (NASDAQ:TTNP)

$0.35

+0.02 (+6.06%)

(As of 11/30/2023 ET)

Compare

Today's Range: $0.34
▼
$0.35
50-Day Range: $0.33
▼
$0.50
52-Week Range: $0.31
▼
$1.09

Volume: 3,734 shs
Average Volume: 20,741 shs
Market Capitalization: $5.27 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Titan Pharmaceuticals Stock (NASDAQ:TTNP)

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.

TTNP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TTNP Stock News Headlines

November 26, 2023 | americanbankingnews.com

Head to Head Survey: Titan Pharmaceuticals (NASDAQ:TTNP) vs. Ignyte Acquisition (NASDAQ:IGNY)

November 23, 2023 | americanbankingnews.com

Titan Pharmaceuticals (NASDAQ:TTNP) Coverage Initiated at StockNews.com

December 1, 2023 | Tomorrow Investor (Ad)

The Only Practical Solution to the World’s Looming Energy Crisis

There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!

October 16, 2023 | finance.yahoo.com

Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors

September 18, 2023 | seekingalpha.com

Titan Pharmaceuticals reports $9.5M private placement of convertible preferred stock

September 18, 2023 | finance.yahoo.com

Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock

August 28, 2023 | finance.yahoo.com

Unveiling Titan Pharmaceuticals (TTNP)'s Value: Is It Really Priced Right? A Comprehensive Guide

August 13, 2023 | thestreet.com

Titan Pharmaceuticals (TTNP) Stock Soars on FDA Committee Treatment Approval

December 1, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

July 27, 2023 | finance.yahoo.com

Titan Pharmaceuticals Announces Sale of Certain ProNeura Assets

June 29, 2023 | usatoday.com

Patents, lawsuits, safety concerns — then tragedy. A timeline of OceanGate's Titan sub.

May 26, 2023 | finance.yahoo.com

TTNP - Titan Pharmaceuticals, Inc.

May 23, 2023 | sports.yahoo.com

Watch: Prowling tiger bows to ‘titan herd’ of elephants

March 22, 2023 | seekingalpha.com

TTNP Titan Pharmaceuticals, Inc.

December 15, 2022 | finance.yahoo.com

Titan Pharmaceuticals Provides Shareholder Update

December 12, 2022 | nz.finance.yahoo.com

Titan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc.

November 21, 2022 | bizjournals.com

Chapel Hill surgical tech company shapes plan to keep Nasdaq listing

November 17, 2022 | finance.yahoo.com

Titan Pharmaceuticals Third Quarter 2022 Earnings: US$0.18 loss per share (vs US$0.19 loss in 3Q 2021)

November 4, 2022 | msn.com

Titan, GAIL, TVS Motor, Britannia & Other Stocks to Release Q2 Results Today

August 17, 2022 | benzinga.com

Titan Pharmaceuticals Announces Board Expansion...

August 16, 2022 | finance.yahoo.com

Titan Pharmaceuticals Announces Board Expansion and Management Changes

July 11, 2022 | insidermonkey.com

Hedge Fund and Insider Trading News: George Soros, Jim Simons, Three Arrows Capital, Rocket Companies Inc (RKT), Titan Pharmaceuticals, Inc. (TTNP), and More

July 11, 2022 | finance.yahoo.com

Activist Investing Nominates Slate of Highly Qualified Director Candidates for Election to the Board of Directors of Titan Pharmaceuticals at Upcoming Special Meeting of Stockholders

July 9, 2022 | finance.yahoo.com

Here's Why We're Watching Titan Pharmaceuticals' (NASDAQ:TTNP) Cash Burn Situation

July 6, 2022 | benzinga.com

Titan Pharmaceuticals Gets FDA Clearance To Commence Opioid Disorder Study

July 5, 2022 | nasdaq.com

Titan Pharma Says FDA Clears IND Application For Nalmefene Implant

July 5, 2022 | finance.yahoo.com

Titan Pharmaceuticals Announces FDA Clearance of IND Application for Nalmefene Implant

See More Headlines

Receive TTNP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Titan Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/30/2021
Today: 12/01/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/13/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TTNP
CUSIP: N/A
CIK: 910267
Web: www.titanpharm.com
Phone: (650) 244-4990
Fax: 650-244-4956
Employees: 4
Year Founded: 1992

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-10,210,000.00
Net Margins: -2,021.31%
Pretax Margin: -2,021.31%
Return on Equity: -302.61%
Return on Assets: -144.74%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.30
Quick Ratio: 5.30

Sales & Book Value

Annual Sales: $560,000.00
Price / Sales: 9.42
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.54 per share
Price / Book: 0.65

Miscellaneous

Outstanding Shares: 15,070,000
Free Float: 10,863,000
Market Cap: $5.27 million
Optionable: Optionable
Beta: 1.41

Social Links

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. David Elliot Lazar (Age 32)
CEO & Principal Financial Officer
Comp: $726.08k
Dr. Katherine L. Beebe-DeVarney Ph.D. (Age 62)
President, COO & Director
Comp: $308k
Mr. Mike Fritz
National Sales Director
Jennifer Kiernan
Executive Assistant to CEO & Investor Communications Coordinator
Joe Schrei
Executive Director of Commercial Operations

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

TTNP Stock Analysis - Frequently Asked Questions

How have TTNP shares performed in 2023?: Titan Pharmaceuticals' stock was trading at $0.7831 at the beginning of 2023. Since then, TTNP stock has decreased by 55.3% and is now trading at $0.35.
View the best growth stocks for 2023 here.
When is Titan Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024.
View our TTNP earnings forecast.
How were Titan Pharmaceuticals' earnings last quarter?: Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) posted its quarterly earnings results on Tuesday, March, 30th. The specialty pharmaceutical company reported ($0.86) EPS for the quarter, topping the consensus estimate of ($1.33) by $0.47. Titan Pharmaceuticals had a negative net margin of 2,021.31% and a negative trailing twelve-month return on equity of 302.61%.
When did Titan Pharmaceuticals' stock split?: Titan Pharmaceuticals shares reverse split on Tuesday, December 1st 2020. The 1-30 reverse split was announced on Monday, November 30th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, November 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Titan Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Titan Pharmaceuticals investors own include Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), Organigram (OGI), Zosano Pharma (ZSAN), Novan (NOVN), ADMA Biologics (ADMA), Aeterna Zentaris (AEZS), CNBX Pharmaceuticals (CNBX) and Pennsylvania Real Estate Investment Trust (PEI).
Who are Titan Pharmaceuticals' major shareholders?: Titan Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends.
How do I buy shares of Titan Pharmaceuticals?: Shares of TTNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:TTNP) was last updated on 12/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial